Market Access
In the Belgian landscape, Market Access is shaped by a stringent regulatory and reimbursement framework, requiring strategic navigation of FAMHP for market authorization and RIZIV/INAMI for pricing and reimbursement. The system emphasizes health technology assessment (HTA), where clinical and economic value drive decision-making. The focus on cost containment, combined with evolving policies around innovation and real-world evidence, makes the Belgian landscape both challenging and dynamic, and early stakeholder engagement for companies a must.
Healixia has established a Market Access working group since 2025, in response to interest from our members. With this initiative, we aim to strengthen our members professionally by offering training and networking opportunities on different relevant Market Access topics.
We would like to capture which topics are most relevant to Market Access professionals through the short survey below. This will help us tailor our initiatives to the needs and interests of our members.
Members of the Market Access education group

Erik Present
Benelux Medical Director at Kintiga

Katrien Van Geyt
Axes Health BV

Bart Van Den Daele
GILEAD Sciences Belgium bv

Stefaan Vansieleghem
HEBIAS bv

Marlies Boeren
Kintiga

Cédric Libert
GILEAD Sciences Belgium bv

Glen Vandyck
GILEAD Sciences Belgium bv

Aline Lescrauwaet
Sandoz nv/sa

Jens Motmans
SCS Boehringer Ingelheim Comm.V

Marjan Willaert
pharma.be

Arne Martens
E&A Pharma
Market Access agenda
-
05 June '25
The new KCE health economics guidelines 2025: how to deal with uncertainties
GrimbergenJoin us for an exclusive event dedicated to exploring the upcoming KCE Health Economics (HE) Guidelines for 2025. Discover how these guidelines address key uncertainties and their implications for healthcare decision-making at national and international levels.